{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:45:18Z","timestamp":1790678718624,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["contemporaryclinicaltrials.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.cct.2013.09.014","type":"journal-article","created":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T14:51:01Z","timestamp":1381157461000},"page":"555-564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":300,"title":["Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial"],"prefix":"10.1016","volume":"36","clinical-trial-number":[{"clinical-trial-number":"isrctn83772183","registry":"10.18810\/isrctn"}],"member":"78","reference":[{"key":"10.1016\/j.cct.2013.09.014_bb0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"Br Med J"},{"issue":"9759","key":"10.1016\/j.cct.2013.09.014_bb0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.cct.2013.09.014_bb0015","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/archneur.57.11.1586","article-title":"Anti-inflammatory drugs protect against Alzheimer disease at low doses","volume":"57","author":"Broe","year":"2000","journal-title":"Arch Neurol"},{"issue":"21","key":"10.1016\/j.cct.2013.09.014_bb0020","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1001\/jama.2012.5034","article-title":"Association of aspirin use with major bleeding in patients with and without diabetes","volume":"307","author":"De Berardis","year":"2012","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.cct.2013.09.014_bb0025","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jama.280.22.1930","article-title":"Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials","volume":"280","author":"He","year":"1998","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.cct.2013.09.014_bb0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians' Health Study","volume":"321","author":"Steering Committee of the Physicians' Health Study Research Group","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cct.2013.09.014_bb0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","article-title":"Randomised trial of prophylactic daily aspirin in British male doctors","volume":"296","author":"Peto","year":"1988","journal-title":"BMJ"},{"key":"10.1016\/j.cct.2013.09.014_bb0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice","volume":"357","author":"Collaborative Group of the Primary Prevention Project (PPP)","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2013.09.014_bb0045","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2013.09.014_bb0050","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk","volume":"351","author":"The Medical Research Council's General Practice Research Framework","year":"1998","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.cct.2013.09.014_bb0055","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cct.2013.09.014_bb0060","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1532-5415.1991.tb02494.x","article-title":"Rationale for a primary prevention study using low-dose aspirin to prevent coronary and cerebrovascular disease in the elderly","volume":"39","author":"Silagy","year":"1991","journal-title":"JAGS"},{"issue":"6","key":"10.1016\/j.cct.2013.09.014_bb0065","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1532-5415.1994.tb06864.x","article-title":"The PACE pilot study: 12-month results and implications for future primary prevention trials in the elderly. (Prevention with low-dose aspirin of cardiovascular disease in the elderly)","volume":"42","author":"Silagy","year":"1994","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"10.1016\/j.cct.2013.09.014_bb0070","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2165\/00002512-200320120-00004","article-title":"Rationale for a primary prevention trial in the elderly of low dose aspirin for the prevention of major adverse cardiovascular events and vascular dementia in Australian general practice. ASPirin in Reducing Events in the Elderly (ASPREE)","volume":"20","author":"ASPREE Study Group","year":"2003","journal-title":"J Drugs Aging"},{"key":"10.1016\/j.cct.2013.09.014_bb0075","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5694\/j.1326-5377.2008.tb01932.x","article-title":"Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study","volume":"189","author":"Nelson","year":"2008","journal-title":"Med J Aust"},{"key":"10.1016\/j.cct.2013.09.014_bb0080","series-title":"With special feature on socioeconomic status and health","author":"National Center for Health Statistics. Health, United States","year":"2011"},{"issue":"8","key":"10.1016\/j.cct.2013.09.014_bb0085","first-page":"314","article-title":"The Modified Mini-Mental State (3MS) examination","volume":"48","author":"Teng","year":"1987","journal-title":"J Clin Psychol"},{"key":"10.1016\/j.cct.2013.09.014_bb0090","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2190\/UURL-2RYU-WRYD-EY3K","article-title":"A measure of primary sociobiological functions","volume":"6","author":"Katz","year":"1976","journal-title":"Int J Health Serv"},{"key":"10.1016\/j.cct.2013.09.014_bb0095","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.cct.2013.09.014_bb0100","series-title":"Symbol Digit modalities Test (SDMT). Manual (revised)","author":"Smith","year":"1982"},{"key":"10.1016\/j.cct.2013.09.014_bb0105","series-title":"Hopkins Verbal Learning Test \u2014 revised","author":"Brandt","year":"2001"},{"issue":"2","key":"10.1016\/j.cct.2013.09.014_bb0110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/arclin\/18.2.153","article-title":"The reliability of cluster and switch scores for the Controlled Oral Word Association Test","volume":"18","author":"Ross","year":"2003","journal-title":"Arch Clin Neuropsychol"},{"key":"10.1016\/j.cct.2013.09.014_bb0115","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/014662167700100306","article-title":"The CES-D scale: a self report depression scale for research in the general population","volume":"1","author":"Radloff","year":"1977","journal-title":"Appl Psychol Meas"},{"issue":"11","key":"10.1016\/j.cct.2013.09.014_bb0120","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/gerona\/61.11.1157","article-title":"Effects of a physical activity intervention on measures of physical performance: results of the Lifestyle Interventions and Independence for Elders Pilot (LIFE-P) Study","volume":"61","author":"LIFE Study Investigators","year":"2006","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"3","key":"10.1016\/j.cct.2013.09.014_bb0125","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"issue":"11","key":"10.1016\/j.cct.2013.09.014_bb0130","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychol"},{"key":"10.1016\/j.cct.2013.09.014_bb0135","series-title":"Color Trails Test Professional Manual","author":"D'Elia","year":"1996"},{"issue":"10","key":"10.1016\/j.cct.2013.09.014_bb0140","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/archneur.1996.00550100142023","article-title":"Age at onset and pattern of neuropsychological impairment in mild early-stage Alzheimer disease: a study of a community-based population","volume":"53","author":"Reid","year":"1996","journal-title":"Arch Neurol"},{"issue":"12","key":"10.1016\/j.cct.2013.09.014_bb0145","doi-asserted-by":"crossref","first-page":"941","DOI":"10.7326\/0003-4819-113-12-941","article-title":"Clarifying confusion: the confusion assessment method. A new method for detection of delirium","volume":"113","author":"Inouye","year":"1990","journal-title":"Ann Intern Med"},{"issue":"4 Suppl. 3","key":"10.1016\/j.cct.2013.09.014_bb0150","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1097\/01.wad.0000213873.25053.2b","article-title":"ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials","volume":"20","author":"Galasko","year":"2006","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.cct.2013.09.014_bb0160","series-title":"Survival analysis and epidemiological tables manual for Stata Statistical Software: release 10 ed","author":"StataCorp","year":"2007"},{"issue":"20","key":"10.1016\/j.cct.2013.09.014_bb0165","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1002\/sim.1557","article-title":"Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues","volume":"22","author":"Sankoh","year":"2003","journal-title":"Stat Med"},{"key":"10.1016\/j.cct.2013.09.014_bb0170","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0140-6736(05)61034-3","article-title":"Multiplicity in randomized trials I: endpoints and treatments","volume":"365","author":"Schulz","year":"2005","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.cct.2013.09.014_bb0175","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","article-title":"The prevention and treatment of missing data in clinical trials","volume":"367","author":"Little","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cct.2013.09.014_bb0180","article-title":"Group sequential tests with applications to clinical trials","author":"Jennison","year":"2000"},{"issue":"18","key":"10.1016\/j.cct.2013.09.014_bb0185","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2013.09.014_bb0190","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cct.2013.09.014_bb0195","series-title":"Alzheimer disease","first-page":"95","article-title":"Epidemiology of dementia and Alzheimer disease","author":"Kawas","year":"1999"},{"issue":"1","key":"10.1016\/j.cct.2013.09.014_bb0200","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1212\/WNL.56.1.49","article-title":"Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan","volume":"56","author":"Tang","year":"2001","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.cct.2013.09.014_bb0205","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jama.285.6.739","article-title":"Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana","volume":"285","author":"Hendrie","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2013.09.014_bb0215","author":"U.S. CDC Statistics"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714413001651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714413001651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T08:23:02Z","timestamp":1596615782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714413001651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1551714413001651"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2013.09.014","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2013.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}